Generics (UK) Ltd v H Lundbeck A/S

A claim to a product is sufficiently enabled if the specification discloses one way of making it, because the product is the invention, unlike in Biogen.

Citation
[2009] UKHL 12, [2009] RPC 13
Court
House of Lords
Year
2009
Subject
Intellectual Property Law
Topic
Patents: patentability and validity

Facts

Lundbeck held a patent for escitalopram, an anti depressant, which is one of the two enantiomers of citalopram. The patent disclosed one method of separating the enantiomers. Generics argued that the claim to escitalopram itself was invalid for insufficiency, because it covered the product however it was made, but the specification disclosed only one way of making it, so the claim was broader than the technical contribution.

Legal principle

The House of Lords held that the claim was valid. The House said that the principle in Biogen v Medeva, that a claim must not be broader than the technical contribution, did not mean that a claim to a new product was invalid merely because the specification described only one way of making it. The technical contribution was the product itself, which was new, and since the specification enabled the skilled person to make the product, the claim was sufficient. Biogen was concerned with a claim to a product defined by reference to a broad principle, which was different.

Related cases on patents: patentability and validity

Studying intellectual property law? Our tutors help you understand and apply cases like this in essays, problem questions and exams. Request a quote or browse our law notes.

Back to all law cases

This summary is for study and revision and is not legal advice. Although our case summaries are checked for accuracy, we do not guarantee that they are free from errors or omissions. Always read the full judgment for the court's reasoning.

Contact Us

Enquire about our bespoke academic solutions